secwatch.observer — SEC 8-K summary
======================================

Issuer:     BECTON DICKINSON & CO (BDX)
CIK:        0000010795
Form:       8-K
Filed at:   2026-02-09T23:59:59+00:00
Accession:  0001628280-26-006182
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BD Q1 revenue $5.25B beats; closes Waters deal; affirms FY26 guidance
---------------------------------------------------------------------

- Revenue $5.252B (+1.6% reported, +0.4% FX neutral); GAAP EPS $1.34, adjusted EPS $2.91.
- BD to close combination of Biosciences & Diagnostic Solutions business with Waters Corporation on Feb 9, 2026.
- Affirms FY26 revenue growth guidance; provides New BD adjusted diluted EPS guidance.
- Announced $110M investment for Neopak syringe production in Nebraska; FDA clearance for EnCor EnCompass biopsy system.
- Adjusted diluted EPS $2.91, down 15.2% YoY on reported basis but beat expectations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/0001628280-26-006182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10795/000162828026006182/bdx-20260209.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-006182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer